Yoshiko Atsuta
A5046989635- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
- T-cell and Retrovirus Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Mesenchymal stem cell research
- Transplantation: Methods and Outcomes
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Childhood Cancer Survivors' Quality of Life
- Immunodeficiency and Autoimmune Disorders
- Vector-Borne Animal Diseases
- Eosinophilic Disorders and Syndromes
- Hematological disorders and diagnostics
- CAR-T cell therapy research
- Animal Disease Management and Epidemiology
Aichi Medical University
2021-2025
The Japanese Data Center for Hematopoietic Cell Transplantation
2016-2025
Nagoya University
2015-2024
College of Healthcare Management
2021
Osaka University
2021
Kyoto University
2021
Aichi Medical University Hospital
2020
Dokkyo Medical University
2020
Hôpital Saint-Antoine
2019
Sorbonne Université
2019
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) time. This study used central database Center for International Blood Marrow Transplant Research (CIBMTR) to describe time cGVHD incidence, nonrelapse mortality, risk factors cGVHD. The 12-year period was divided into 3 intervals, 1995 1999, 2000 2003, 2004 2007, included 26,563 patients with acute leukemia, myeloid...
Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (eg, umbilical cord blood) older patients using less intense conditioning regimens also contributed an increase the number HCT survivors. These survivors are at risk developing late complications secondary pre-, peri-, posttransplantation exposures factors. Guidelines...
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries individual centers. In 2016, 82,718 first HCT were reported 1,662 teams in 86 195 World Health Organization states representing a global increase 6.2% autologous 7.0% allogeneic bringing total to 1,298,897 procedures. Assuming frequency 84,000/year, 1.5 million performed 2019...
Abstract Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features DDX41-mutated MNs remain to be elucidated. Here we performed a comprehensive characterization MNs, enrolling total 346 patients with pathogenic/likely-pathogenic (P/LP) germ and/or somatic mutations from 9082 MN patients, together 525 first-degree relatives and wild-type (WT) patients. P/LP explained ∼80% known predisposition...
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. However, TA-TMA a clinical diagnosis, multiple criteria have been proposed without universal application. Although some patients self-resolving disease, others progress to multiorgan failure and/or death. Poor prognostic features also are not uniformly accepted. The lack harmonization...
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications international access improves, the number of HCTs performed annually continues rise. Parallel improvements in HCT techniques supportive care entails more patients surviving long term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary pretransplantation, peritransplantation, post-transplantation exposures other underlying factors....
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable curing these diseases. Allo-HCT has been also shown be curative in benign disorders such as aplastic anemia, sickle disease, and thalassemia, among others. Recently, the American Society for Transplantation Cellular Therapy (ASTCT) published standardized definitions recovery, graft rejection, failure, poor function,...
Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal for which prognosis typically poor without timely diagnosis. To explore the safety and efficacy standard chemotherapy combined with central nervous system (CNS)-directed therapy, we conducted multicentre, single-arm, phase 2 trial in untreated IVLBCL patients CNS involvement at diagnosis (PRIMEUR-IVL). In primary analysis, PRIMEUR-IVL study demonstrated 2-year progression-free survival (PFS) 76% overall (OS) 92% low...
Background. There is no standard management of reactivation hepatitis B virus (HBV) infection in HBV-resolved patients without surface antigen (HBsAg), but with antibodies against core and/or HBsAg (anti-HBs). Methods. We conducted a prospective observational study to evaluate the occurrence HBV by serial monthly monitoring DNA and establish preemptive therapy guided this B-cell non-Hodgkin lymphoma (B-NHL) treated rituximab plus corticosteroid-containing chemotherapy (R-steroid-chemo). The...
The number of long-term survivors after hematopoietic stem cell transplantation (HSCT) showed steady increase in the past two decades. Second malignancies HSCT are a devastating late complication. We analyzed incidence of, risk compared with that general population, and factors for secondary solid cancers.Patients were 17 545 adult recipients first allogeneic between 1990 2007 Japan. Risks developing tumors population by using standard ratios (SIRs).Two-hundred sixty-nine cancers identified....
To investigate an up-to-date alternative donor selection strategy, we compared the transplantation outcomes of 8/8 and 7/8 allele–matched unrelated bone marrow (UBMT) with those umbilical cord blood (UCBT) redefined role UCBT extended analysis. Using Cox competing risk regression analyses, analyzed in adult patients acute lymphoblastic leukemia (ALL) myeloid (AML). A total 2472 first myeloablative transplantations between 2000 2010 were included (8/8 UBMT, 1001; 656; UCBT, 815). For chronic...